Literature DB >> 9148261

Strabismus surgery in ocular myasthenia gravis.

H Ohtsuki1, S Hasebe, M Okano, T Furuse.   

Abstract

We evaluated the efficacy of eye muscle surgery in 4 patients with ocular myasthenia gravis with troublesome diplopia. All patients were in remission and had shown a consistently stable angle of deviation for at least 6 months preoperatively. The extent of eye muscle surgery was based on the degree of deviation in the primary position, and conventional recession and resection procedures were performed in 3 patients and hang-loose recession with an adjustable recession in 1. Single binocular vision was obtained in 3 patients in the primary position without prism correction or compensatory head posture. Electron-microscopic studies on the eye muscle specimens obtained at strabismus surgery revealed non-specific degenerative findings for the muscle fibers and sarcomeric disorganization compared to that in a control extraocular muscle.

Entities:  

Mesh:

Year:  1996        PMID: 9148261     DOI: 10.1159/000310681

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  4 in total

1.  Strabismus surgery in the management of diplopia caused by myasthenia gravis.

Authors:  O C Morris; J O'Day
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

2.  Strabismus surgery and long-term visual outcomes in patients with preadolescent onset ocular myasthenia gravis.

Authors:  Jinu Han; So Young Han; Sueng-Han Han; Jong Bok Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-16       Impact factor: 3.117

3.  Treatment for diplopia in patients with myasthenia gravis.

Authors:  Kyung-Ah Park; Sei Yeul Oh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-30       Impact factor: 3.117

4.  Long-term follow-up of strabismus surgery for patients with ocular myasthenia gravis.

Authors:  Jason H Peragallo; Federico G Velez; Joseph L Demer; Stacy L Pineles
Journal:  J Neuroophthalmol       Date:  2013-03       Impact factor: 3.042

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.